News & Updates
Filter by Specialty:
Long-term tapinarof use proven safe, effective in plaque psoriasis
Continuous and intermittent use of tapinarof cream 1% once daily (QD) for up to 1 year is effective in patients with mild-to-severe plaque psoriasis, without serious safety concerns, according to a study. In addition, it has shown durable efficacy and a remittive effect of at least 4 months off therapy.
Long-term tapinarof use proven safe, effective in plaque psoriasis
21 Oct 2022SLN status delivers vital prognosis in stage IIB/C cutaneous melanoma
The status of sentinel lymph nodes (SLN) can help predict the course of the disease in patients with clinical stage IIB/C cutaneous melanoma, suggests a study.
SLN status delivers vital prognosis in stage IIB/C cutaneous melanoma
17 Oct 2022Comorbidity burden heavier in generalized pustular psoriasis
Patients with generalized pustular psoriasis (GPP) suffer from a heavier burden of comorbidities than the general population and comparators with psoriasis vulgaris (PV), a new study has found.
Comorbidity burden heavier in generalized pustular psoriasis
17 Oct 2022Skin type factors in dupilumab efficacy in atopic dermatitis
The use of dupilumab in the treatment of atopic dermatitis appears to benefit patients who have dark skin types more than those who have light skin types, as shown in a study.